OBJECTIVE： To provide reference for clinical individual medication of voriconatole. METHODS： The distribution of MIC of voriconazole to Aspergillus fumigatus and Candida albicans were summarized as well as the pharmacokinetic parameters of voriconazole in different populations. Using probability of target attainment （PTA） and cumulative fraction of response （CFR） as indexes， crystal ball software 11.1.2.4 was used for Monte Carlo simulation of different dosage regimens of same population and same dosage regimen of different populations. RESULTS： For children with impaired immunity， when the drug doses of were 4， 6 mg/kg and MIC was lower than 0.125 mg/L， PTA was higher than 90％； when the drug doses was increased to 8 mg/kg and MIC was lower than 0.125 mg/L， PTA was higher than 90％. For different populations receiving same dosage regimens （4 mg/kg）， MIC of teenagers with impaired immunity was lower than 0.25 mg/L and those of healthy adults， patients underwent hematopoietic stem cell transplantation and adults with impaired immunity were all lower than 0.5 mg/L， PTA was higher than 90％. CFR to A. fumigatus were 42.53％， 58.41％， 77.74％， 70.16％， 89.40％， 93.72％， 95.42％ and CFR to C. albicans were 96.68％， 97.13％， 97.94％， 97.54％， 98.07％， 98.28％， 98.35％ among children with impaired immunity receiving different drug doses （4， 6， 8 mg/kg） and different populations receiving drug dose of 4 mg/kg （teenagers with impaired immunity， healthy adults， patients underwent hematopoietic stem cell transplantation， adults with impaired immunity）. CONCLUSIONS： Various dosage regimens of different populations included in this study could effectively control C. albicans infection. It is necessary to increase the drug dose of children and teenagers with impaired immunity in order to meet the needs of A. fumigatus infection treatment.